I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Avastin (Bevacizumab) for Retinal Conditions: What Patients Should Know
How Avastin Works in the Eye
Bevacizumab works by targeting a specific protein that drives abnormal blood vessel growth in the retina. Understanding this mechanism helps explain why it is effective for several different retinal conditions.
Vascular endothelial growth factor, commonly known as VEGF, is a protein the body produces to signal the growth of new blood vessels. In healthy tissue, this process supports healing. But in the retina, the thin light-sensitive layer at the back of the eye, elevated VEGF levels can trigger the growth of abnormal, fragile blood vessels.
These new vessels leak fluid or blood into surrounding tissue, causing swelling in the macula. The macula is the small central area of the retina responsible for sharp, detailed vision. When fluid accumulates there, everyday tasks like reading, driving, and recognizing faces can become difficult.
Bevacizumab is a full-length monoclonal antibody, a type of laboratory-made protein designed to seek out and bind to VEGF-A. By attaching directly to this protein, it prevents VEGF from reaching the receptors on blood vessel walls that trigger abnormal vessel growth and leakage.
Once the VEGF signal is blocked, the drive for new vessel growth is reduced. Fluid in the retina can begin to decrease, and retinal tissue can stabilize. This is the same basic mechanism shared by all anti-VEGF medications used in retinal care, though each drug has its own molecular structure and dosing characteristics.
Avastin received FDA approval as a cancer treatment, not as an eye medication. When used for cancer, it is given intravenously in large doses. Retina specialists discovered that a much smaller dose, delivered directly into the eye, could effectively target the same VEGF protein involved in retinal disease.
Because the cancer-treatment vial contains far more medication than is needed for a single eye injection, it is sent to a compounding pharmacy, where it is divided into smaller doses appropriate for intravitreal use, meaning injection directly into the eye. This compounding process has been in place since 2005 and is performed by regulated facilities that follow strict sterility standards.
What the Research Shows
Bevacizumab has been studied in large, rigorously designed clinical trials. The results have helped establish it as a clinically effective option alongside FDA-approved alternatives for retinal care.
The Comparison of Age-Related Macular Degeneration Treatments Trials, known as the CATT trial, enrolled more than 1,200 patients at 44 clinical centers across the United States. The study directly compared bevacizumab, used off-label, to ranibizumab (Lucentis), which holds FDA approval for wet age-related macular degeneration.
Results showed that both medications produced equivalent vision improvements. Patients receiving monthly bevacizumab gained an average of 8.0 letters on a standardized vision chart, compared to 8.5 letters for patients receiving monthly ranibizumab. This landmark trial established bevacizumab as a clinically effective option for treating wet AMD.
The IVAN trial, conducted in the United Kingdom, confirmed the CATT findings, showing that bevacizumab and ranibizumab produced comparable visual outcomes for patients with wet AMD. Beyond AMD, bevacizumab has also been evaluated in patients with diabetic macular edema (DME) and macular edema caused by retinal vein occlusion, a condition in which a vein in the retina becomes blocked and causes fluid buildup. Research supports its effectiveness for both of these conditions, and it is commonly used across all three indications in clinical practice.
Five-year follow-up data from the CATT trial showed that approximately half of treated patients maintained visual acuity of 20/40 or better, a level that supports many daily activities including driving. Some patients experienced gradual vision decline after the first two years of treatment, which underscores the importance of consistent, long-term monitoring and care. Overall, the long-term data confirm that anti-VEGF treatment, including bevacizumab, provides meaningful visual benefit for many patients with wet AMD when used consistently.
The Injection Process: What to Expect
Many patients feel anxious about receiving an injection into the eye. Knowing what happens at each step makes the process feel much more manageable. The procedure is brief, carefully performed, and designed with your comfort in mind.
Before the injection, your retina specialist will apply anesthetic (numbing) drops to the surface of your eye. An antiseptic solution is also applied to reduce the risk of infection. Some patients receive a small additional numbing injection near the eye for extra comfort. The preparation takes only a few minutes and is a standard part of every procedure.
The injection itself takes just a few seconds. Your specialist uses a very fine needle to deliver the medication through the sclera, the white outer layer of the eye, and into the vitreous, the clear gel that fills the inside of the eye. Most patients feel brief pressure rather than sharp pain. The full appointment, from arrival to departure, typically takes between 30 minutes and one hour.
Mild redness at the injection site, a gritty or scratchy feeling, and slightly blurred vision are common for a few hours after the procedure. These effects are expected and usually resolve on their own within a day. Your specialist may check your eye pressure before you leave the office.
You can return to most normal daily activities the same day. Avoid rubbing your eye, swimming, or spending time in dusty environments for a few days after the injection to reduce the risk of infection.
Treatment Schedule and Frequency
Because bevacizumab does not permanently stop VEGF production in the eye, ongoing treatment is usually necessary to maintain results. Your treatment schedule will be tailored to your specific diagnosis and how your retina responds over time.
Most patients begin with a series of monthly injections, often referred to as a loading phase. This initial period, typically lasting two to three months, is designed to bring fluid levels in the retina under control quickly. The number of starting injections depends on the severity of your condition and how your retina responds to early treatment.
Once the retina is stable on imaging, many specialists use a treat-and-extend strategy. The interval between injections is gradually extended, often by two weeks at a time, as long as imaging confirms that no fluid has returned. If fluid reappears on a scan, the interval is shortened again.
This approach allows treatment to continue while reducing the number of clinic visits needed over time. It balances the effectiveness of ongoing therapy with the practical demands of your schedule and daily life.
Most retinal conditions treated with anti-VEGF injections require long-term maintenance. Stopping injections prematurely, even when your vision feels stable, can allow fluid to return and lead to further vision decline. If you need to reschedule an appointment, contact your specialist as early as possible to minimize gaps between treatments.
Benefits and Risks of Bevacizumab
Like all medical treatments, bevacizumab has both established benefits and potential risks. Your retina specialist will review these with you in the context of your individual diagnosis and health history.
Multiple large clinical trials have confirmed that bevacizumab is effective for treating wet AMD, diabetic macular edema, and macular edema from retinal vein occlusion. The CATT trial demonstrated vision outcomes comparable to FDA-approved alternatives. A review of more than 6,000 intravitreal bevacizumab injections found that serious complications occurred in fewer than 0.1% of cases, reflecting a well-established safety record when the medication is obtained from regulated sources and administered under proper conditions.
The side effects most often reported after an intravitreal injection are mild and temporary. They are common to all eye injections, not unique to bevacizumab, and typically resolve on their own within a few days. These may include:
- Redness at the injection site
- A gritty or scratchy sensation in the eye
- Brief blurred vision
- Floaters (small spots or shapes that drift across your vision)
- Watery eyes
If any of these effects persist beyond a few days or seem to be getting worse, contact your specialist's office promptly.
Serious complications are uncommon but possible with any intravitreal injection. Rare risks include:
- Endophthalmitis, a serious infection inside the eye
- Retinal detachment
- A significant increase in eye pressure
- Bleeding inside the eye
Because bevacizumab is repackaged at compounding pharmacies rather than produced in single-use vials designed for eye injection, maintaining proper sterility during this process is an important safety consideration. Our practice obtains bevacizumab from trusted, regulated compounding sources. Seek care at an emergency room immediately if you experience sudden vision loss, severe eye pain, or rapidly worsening redness after an injection.
How Bevacizumab Compares to Other Anti-VEGF Medications
Bevacizumab is one of several anti-VEGF options used in retinal care today. Understanding the differences between these medications can help you have a more informed conversation with your retina specialist.
Several anti-VEGF medications hold FDA approval specifically for retinal diseases. These include:
- Eylea (aflibercept), which can be given every four to sixteen weeks depending on treatment response
- Eylea HD (high-dose aflibercept), a newer formulation designed to support longer intervals between injections
- Lucentis (ranibizumab), given monthly or on a treat-and-extend basis
- Vabysmo (faricimab), which targets both VEGF and a second protein called angiopoietin-2 and may allow extended dosing intervals
Clinical trials have shown that bevacizumab produces visual outcomes comparable to these FDA-approved options for wet AMD, though individual responses can vary. Your specialist will help determine which medication is most appropriate for your diagnosis and circumstances.
The most important distinction between bevacizumab and FDA-approved retinal medications is regulatory status. Bevacizumab is not approved by the FDA for eye use and must be repackaged from cancer-treatment vials at a compounding pharmacy. FDA-approved retinal drugs are manufactured in single-use vials designed specifically for intravitreal injection.
Cost is also a meaningful factor. Bevacizumab is substantially less expensive per dose than FDA-approved alternatives. For patients who require injections over many months or years, this difference can be significant, particularly when factoring in insurance coverage, copays, and out-of-pocket expenses. Your specialist can walk you through all available options and help you choose the one that best fits your medical and personal needs.
Recovery and Ongoing Monitoring
Recovery after each injection is generally brief and straightforward. Consistent follow-up is one of the most important factors in protecting your vision over the long term.
Most patients can return to their normal routine within a few hours of the injection. Your vision may be slightly blurred for the remainder of the day due to the numbing drops and the injection itself. We recommend arranging for a driver to take you home from your appointment. For the first few days, avoid rubbing your eye, swimming, or being in environments with dust or debris to reduce infection risk.
Your retina specialist will schedule regular follow-up visits that include vision testing and retinal imaging. Optical coherence tomography, called OCT, is a painless, non-invasive scan that creates a detailed cross-section of your retina. It allows your specialist to detect even small amounts of fluid or swelling that may not yet be affecting your vision. These imaging results directly guide decisions about your treatment interval and any adjustments needed.
Some symptoms after an eye injection require prompt medical evaluation rather than waiting for a scheduled follow-up. Seek care right away if you experience any of the following:
- Sudden or significant vision loss
- Severe eye pain or pressure
- A large or sudden increase in floaters
- New flashes of light
- A shadow or curtain across part of your vision
These symptoms can indicate a serious complication that requires immediate evaluation. Do not wait until your next scheduled appointment if any of these warning signs appear.
Who May Benefit From Bevacizumab
Bevacizumab is used off-label for several retinal conditions involving abnormal blood vessel growth or fluid accumulation in the retina. If you have been diagnosed with one of these conditions, your retina specialist can evaluate whether this treatment is appropriate for you.
The retinal conditions most commonly treated with intravitreal bevacizumab include:
- Wet age-related macular degeneration (wet AMD), in which abnormal blood vessels grow beneath the retina and leak fluid
- Diabetic macular edema (DME), swelling in the macula caused by blood vessel damage related to diabetes
- Macular edema following retinal vein occlusion, a blockage in the veins that drain the retina
- Proliferative diabetic retinopathy, an advanced form of diabetic eye disease involving new vessel growth on or near the retina
Early treatment for these conditions generally leads to better visual outcomes than waiting until significant vision loss has occurred. If you have been diagnosed or are noticing new vision changes, scheduling a retina evaluation promptly is important.
Certain vision changes should prompt a visit to a retina specialist regardless of whether you have an existing diagnosis. A sudden increase in floaters, new flashes of light, a shadow across part of your vision, or sudden vision loss in one eye are all symptoms that require prompt evaluation. These could signal a serious retinal condition that may benefit from early treatment. Our practice welcomes both referred patients and those who reach out to us directly.
Frequently Asked Questions
Here are answers to questions we hear most often from patients considering or currently receiving bevacizumab. If you have additional questions, your care team is glad to help during your visit.
Off-label use is legal and common in medicine when it is supported by strong clinical evidence. Large trials confirmed that bevacizumab produces vision outcomes equivalent to FDA-approved alternatives for wet AMD. Its substantially lower cost per dose also makes it accessible for patients who require frequent injections over years of treatment and may face insurance limitations or significant out-of-pocket costs. The choice of medication is always made on an individual basis by your retina specialist based on your specific condition, response to treatment, and personal circumstances.
This is a reasonable concern and one our patients often raise. Regulated compounding pharmacies that prepare bevacizumab for eye injection are required to follow specific sterility and quality standards. Our practice obtains bevacizumab from trusted, compliant compounding sources, and the medication is prepared and handled with strict attention to safety protocols. If you have questions about the source or preparation of your specific medication, please ask your specialist before your injection appointment.
Switching medications is possible and sometimes recommended. If your retina is not responding adequately to bevacizumab, or if your specialist believes a different option might better suit your dosing needs or allow longer intervals between visits, a transition may be discussed. Switching does not necessarily mean restarting your treatment from the beginning. Your specialist will guide that decision based on your imaging results, vision stability, and overall health profile.
A single appointment delayed by a short period often does not cause a significant problem, but extended gaps in treatment can allow fluid to return to the retina and may cause vision to worsen. If you need to reschedule, contact our office as soon as possible so we can see you in a timely manner. Do not stop treatment on your own without first discussing the risks of pausing injections with your retina specialist.
Many patients require long-term treatment to maintain their visual gains, but the picture varies by individual. Some patients are able to extend the time between injections significantly as their condition stabilizes, and in some cases treatment may be carefully paused under close monitoring. This is never a fixed decision but rather one that evolves based on your imaging results and vision over time. Your specialist will help you understand what to expect given your specific condition and history.
Cataract surgery is generally compatible with ongoing anti-VEGF treatment, though the timing of injections around surgery is coordinated carefully. Managing a retinal condition alongside a developing cataract is not uncommon, and this type of concurrent care is something our team is experienced in navigating. Your retina specialist and cataract surgeon will communicate directly to plan the timing of both treatments in a way that supports the best outcomes for your overall eye health.
Expert Retinal Care Across Connecticut
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons are committed to providing expert, personalized retinal care to patients throughout Connecticut. Whether you are newly diagnosed, managing a long-standing retinal condition, or seeking a second opinion, we are here to guide you through your options with clarity, honesty, and genuine care. We welcome referred patients, self-referred patients, and those who need urgent evaluations at any of our four conveniently located offices.
30 Years of Care & Commitment
